CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

The Association Between Selective Serotonin Reuptake Inhibitors and Glycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Open access

Abstract

Objective: Individual studies have reported conflicting effects of selective serotonin reuptake inhibitors (SSRIs) on glycemia. We systematically reviewed the effects of SSRIs on glycemia and whether metabolic and psychological factors moderated these effects. Methods: We systematically searched for placebo-controlled randomized controlled trials investigating the effect of SSRIs on glycemia (fasting blood glucose or HbA1c) as a primary or secondary outcome. Random effects meta-analysis was conducted to compute an overall treatment effect. Meta-regression tested whether depression, type 2 diabetes, insulin resistance, treatment duration, and weight loss moderated treatment effects. Results: Sixteen randomized controlled trials ( n = 835) were included and glycemia was usually a secondary outcome. Overall, SSRIs improved glycemia versus placebo (pooled effect size (ES) = − 0.34, 95% confidence interval (CI) = −0.48 to −0.21; p < .001, I 2 = 0%). Individually, fluoxetine (ES = − 0.29, 95% CI = −0.54 to −0.05; p = .018) and escitalopram/citalopram (ES = − 0.33, 95% CI = −0.59 to −0.07; p = .012) outperformed placebo, but paroxetine (ES = − 0.19, 95% CI = −0.58 to 0.19; p = .33) did not. Results were similar in populations selected for depression as those not. Across studies, baseline insulin resistance ( p = .46), treatment duration ( p = .47), diabetes status ( p = .41), and weight loss ( p = .93) did not moderate changes. Heterogeneity for all analyses was nonsignificant. Conclusions: SSRIs seem to have an association with improvement in glycemia, which is not moderated by depression status, diabetes status, or change in weight across studies. Future powered trials with longer treatment duration are needed to confirm these findings. Registration: PROSPERO ID: CRD4201809239.

Overview

Integrity signals

Registry

Crossref · 10.1097/psy.0000000000000707

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. 2016, The selective serotonin reuptake inhibitor fluoxetine promotes insulin secretion and maintains functional beta cell mass, Diabet Med, 33, 20

Cited by

See all 37

Metadata

Authors
Tharmaraja, T., Stahl, D., Hopkins, C. W. P., Persaud, S. J., Jones, P. M., Ismail, K., & Moulton, C. D.
Affiliations
King's College London (GB)
Corresponding author
Moulton, Calum D.
Venue
Psychosomatic Medicine
Published
2019-05-13
Volume
81
Issue
7
Pages
570-583
ISSN
  • 0033-3174 (ISSN-L)
  • 1534-7796
OpenAlex
W2945494482
Cited by
35
References
47
Citations by year
2026: 5 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 10 · 2021: 3 · 2020: 4 · 2019: 3
FWCI
0.64
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Psychosomatic Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Sanofi
  • Royal College of Physicians of Edinburgh
  • National Institute for Health and Care Research
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
selective serotonin reuptake inhibitors, glycemia, fasting blood glucose, HbA1c, depression, type 2 diabetes, insulin resistance, fluoxetine, paroxetine, escitalopram, citalopram, weight loss
MeSH terms
Blood Glucose, Depressive Disorder, Glycated Hemoglobin, Humans, Comorbidity, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Glucose Metabolism Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Association Between Selective Serotonin Reuptake Inhibitors and Glycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1097/psy.0000000000000707
The paper
Tharmaraja, T., Stahl, D., Hopkins, C. W. P., Persaud, S. J., Jones, P. M., Ismail, K., & Moulton, C. D. (2019). The Association Between Selective Serotonin Reuptake Inhibitors and Glycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Psychosomatic Medicine. https://doi.org/10.1097/psy.0000000000000707

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.